Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: red_dog who wrote (87526)	3/9/2000 8:15:00 AM
From: Sosmartinov	Read Replies (1) \| Respond to of 120523

Under the heading "It ain't what you know": my brother tried to get me interested in TCLN wi one of their recent patents to which I responded, patents are a dime a dozen, it's a long way to a product, etc. cuz I've had a lot of experience wi deflated biotechs and some knowledge of the science. TCLN was about 1.50 at the time. He bot 3K shrs, me none. The rest is history....; the trend is your friend, not the library. The library is a life-long companion, wi not too much dough.

To: red_dog who wrote (87526)	3/9/2000 9:12:00 AM
From: red_dog	Respond to of 120523

Novo Nordisk Expands Research Agreement With DGI BioTechnologies March 9, 2000 08:55 AM Eastern Time EDISON, N.J., March 9 /PRNewswire/ -- DGI BioTechnologies, LLC. (DGI), today announced that its collaborative research partner Novo Nordisk A/S has expanded its research agreement with DGI. Novo Nordisk is a multinational pharmaceutical company based in Bagsvaerd, Denmark, with annual sales of $2.5 billion. The original research agreement, announced in June 1999, provided technology transfer and licensing fees and contains provisions for significant additional payments when specified development milestones are met. The updated agreement expands the scope of the research portion of the contract by providing supplemental funding to support the accelerated pace of research using DGI's patented and proprietary Diogenesis(R) drug-lead-discovery platform. DGI BioTechnologies, LLC., is majority owned by New Brunswick Scientific Co., Inc. NBSC .